NDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
60/100
Clinical Trials
21
Data completeness
6/8 — Strong
Priority Review
AFINITOR DISPERZ (everolimus) by Novartis is protein kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2012.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AFINITOR DISPERZ is an oral tablet-for-suspension formulation of everolimus, an mTOR protein kinase inhibitor approved in 2012. It is indicated for multiple cancer types and non-malignant proliferative disorders where mTOR pathway activation drives disease. The drug works by inhibiting mTOR signaling, which suppresses cell proliferation and angiogenesis.
$5MPart D
PeakProduct is in peak commercial stage with established market presence; mid-to-late-stage teams focused on market penetration and lifecycle management rather than rapid growth.
Mechanism of Action
Protein Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer
Started Dec 2026
50 enrolled
Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaRecurrent Endometrial Carcinoma+2 more
REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia
Started Aug 2026
400 enrolled
Chronic Limb Threatening IschemiaChronic Limb-Threatening Ischemia
To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System
Started Aug 2025
2,000 enrolled
Coronary Artery DiseaseCoronary Artery StenosisPercutaneous Coronary Intervention+1 more
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
Started Aug 2025
140 enrolled
Heart Transplant
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Started Jul 2025
440 enrolled
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Worked on AFINITOR DISPERZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.